A prospective, post -marketing, observational cohort study investigating the long-term safety and effectiveness of denosumab in Japanese patients with osteoporosis
Latest Information Update: 25 May 2021
At a glance
- Drugs Denosumab (Primary)
- Indications Corticosteroid-induced osteoporosis; Osteoporosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Daiichi Sankyo Company
- 25 May 2021 New trial record
- 01 May 2021 Results published in the Journal of Bone and Mineral Metabolism